Clinical details of the parkinsonian patients investigated
| Patient | Age (y) | Sex | Duration (y) | Grading | Treatment |
|---|---|---|---|---|---|
| 1 | 68 | M | 11 | 11 (II) | LD; Se |
| 2 | 79 | M | 3 | 10 (II) | LD; Se |
| 3 | 61 | F | 3 | 5 (II) | LD; Se |
| 4 | 50 | M | 10 | 11 (II) | LD; AC |
| 5 | 63 | M | 5 | 14 (II) | LD |
| 6 | 69 | M | 6 | 8 (II) | LD; Se |
| 7 | 77 | M | 12 | 11 (II) | LD; Se |
| 8 | 68 | M | 10 | 11 (II) | LD; AC; Amant |
| 9 | 58 | M | 12 | 8 (II) | LD; Se; AC |
| 10 | 72 | M | 4 | 9 (II) | LD |
| 11 | 66 | F | 6 | 8 (II) | LD |
| 12 | 62 | M | 6 | 7 (II) | LD; Se |
| 13 | 59 | M | 15 | 11 (II) | LD; Perg |
| 14 | 57 | F | 9 | 7 (II) | LD; Perg |
| 15 | 58 | M | 2 | 9 (II) | LD; Se; Perg |
| 16 | 75 | F | 2 | 7 (II) | LD |
| 17 | 74 | F | 6 | 12 (III) | LD; AC |
| 18 | 67 | F | 7 | 8 (II) | AC; Perg |
| 19 | 55 | M | 12 | 12 (II) | LD; Se; AC |
| 20 | 69 | M | 20 | 15 (II) | LD; AC; Perg |
| 21 | 54 | M | 13 | 10 (II) | LD; AC; Amant; Perg |
| mean | 64.8 | — | 8.3 | 9.7 (—) | — |
| SD | 8.1 | — | 4.7 | 2.5 (—) | — |
Grading refers to the Webster21 rating and, in parentheses, the Hoehn and Yahr20 staging. Duration=Duration of Parkinson’s disease since initial diagnosis; F=female; M=male; LD=levodopa; Se=selegiline; AC=anticholinergic; Amant =amantadine; Perg=pergolide.